Drug
Lumasiran clinical trials
Also written ALN-GO1 and OXLUMO.
Keep track of what changes. Save the lumasiran studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 1
Alnylam Pharmaceuticals (6) · Charite University, Berlin, Germany (1)
Studies
Open first, then newest update. How each study uses lumasiran is read from its arms, and is right about nine times in ten.
Testing it · 7
- Lumasiran in Hyperoxalaemic Patients on HaemodialysisRecruitingPhase 2Charite University, Berlin, GermanyNCT06225544Written as Lumasiran
- A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1CompletedPhase 3Alnylam PharmaceuticalsNCT04152200Written as Lumasiran
- A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1CompletedPhase 3Alnylam PharmaceuticalsNCT03905694Written as Lumasiran
- A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1CompletedPhase 3Alnylam PharmaceuticalsNCT03681184Written as Lumasiran
- A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate LevelsTerminatedPhase 2Alnylam PharmaceuticalsNCT05161936Written as Lumasiran
- An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1CompletedPhase 2Alnylam PharmaceuticalsNCT03350451Written as Lumasiran
- Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1CompletedPhase 1/2Alnylam PharmaceuticalsNCT02706886Written as Lumasiran
Codes
What other systems call lumasiran · ClinicalTrials.gg INT001601
- MeSH (NLM) C000716350lumasiranConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) RZT8C352O1LUMASIRANConfirmed FDA, NLM, Wikidata
- RxNorm 2467140One source FDA
- Wikidata Q100692768lumasiranConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170137LumasiranOne source FDA
- DrugBank DB15935One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000716350 | lumasiran | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | RZT8C352O1 | LUMASIRAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2467140 | — | One source FDA |
| Wikidata | Q100692768 | lumasiran | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170137 | Lumasiran | One source FDA |
| DrugBank | DB15935 | — | One source Wikidata |
Also registered as lumasiran sodium (UNII 67P6XH37HD · RxNorm 2467161).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.